MARKET

ORIC

ORIC

Oric Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

35.97
+0.31
+0.87%
After Hours: 35.86 -0.11 -0.31% 16:27 12/04 EST
OPEN
35.76
PREV CLOSE
35.66
HIGH
36.98
LOW
35.32
VOLUME
121.78K
TURNOVER
--
52 WEEK HIGH
40.67
52 WEEK LOW
18.60
MARKET CAP
1.28B
P/E (TTM)
-22.6554
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ORIC Pharmaceuticals (ORIC) in Focus: Stock Moves 6.7% Higher
ORIC Pharmaceuticals (ORIC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks · 4d ago
ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the closing of its previously announced underwritten public offering of 5,796,000 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 756,000 additional shares of its common stock, at a price to the public of $23.00 per share. The gross proceeds to ORIC from the offering were approximately $133.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.
GlobeNewswire · 11/17 21:15
ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the closing of its previously announced underwritten public offering of 5,796,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 756,000 additional shares of its common stock, at a price to the public of $23.00 per share. The gross proceeds to ORIC from the offering were approximately $133.3 million, before deducting underwriting discounts and commissions and estimated offering expenses. J.P. Morgan Securities LLC, Citigroup, Jefferies LLC and Guggenheim Securities acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. acted as lead manager for the offering.The offering is made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at prospectus-eq_fi@jpmchase.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (800) 831-9146; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, by telephone at (212) 518-9658 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.Registration statements relating to the securities have been filed with the Securities and Exchange Commission and have become effective. A copy of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.About ORIC Pharmaceuticals, Inc.ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California.For more information, please contact:Dominic Piscitelli, Chief Financial Officer dominic.piscitelli@oricpharma.com info@oricpharma.com
GlobeNewswire · 11/17 21:15
Oric Pharma prices stock offering at $23
ORIC Pharmaceuticals (ORIC) prices its public offering of 5.04M common shares at $23.00 per share. Underwriters' over-allotment is an additional 756K shares. Gross proceeds should be ~$115.9M. Closing date is
Seekingalpha · 11/13 12:01
ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of an upsized underwritten public offering of 5,040,000 shares of its common stock at a price of $23.00 per share. All of the shares of common stock are being offered by ORIC. In addition, ORIC has granted the underwriters a 30-day option to purchase up to 756,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to ORIC from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ORIC, are expected to be approximately $115.9 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on November 17, 2020, subject to customary closing conditions.
GlobeNewswire · 11/13 11:32
ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of an upsized underwritten public offering of 5,040,000 shares of its common stock at a price of $23.00 per share. All of the shares of common stock are being offered by ORIC. In addition, ORIC has granted the underwriters a 30-day option to purchase up to 756,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to ORIC from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ORIC, are expected to be approximately $115.9 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on November 17, 2020, subject to customary closing conditions. J.P. Morgan Securities LLC, Citigroup, Jefferies LLC and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. is acting as lead manager for the proposed offering.The offering is made only by means of a prospectus, copies of which may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at prospectus-eq_fi@jpmchase.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (800) 831-9146; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, by telephone at (212) 518-9658 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.Registration statements relating to the securities have been filed with the Securities and Exchange Commission and have become effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.About ORIC Pharmaceuticals, Inc.ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California.Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the terms, timing and completion of the public offering of common stock. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the offering, and other risks. Further information regarding such risks and uncertainties may be found in ORIC’s registration statement on Form S-1 filed with the Securities and Exchange Commission (SEC) on November 10, 2020 and the preliminary prospectus included therein, as well as other documents ORIC files from time to time with the SEC, including ORIC’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.For more information, please contact: Dominic Piscitelli, Chief Financial Officer dominic.piscitelli@oricpharma.com info@oricpharma.com
GlobeNewswire · 11/13 11:32
ORIC Pharmaceuticals Announces Proposed Public Offering of Common Stock
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by ORIC. In addition, ORIC expects to grant the underwriters a 30-day option to purchase an additional 600,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.
GlobeNewswire · 11/10 21:09
The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19)
Benzinga · 10/20 12:17
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORIC. Analyze the recent business situations of Oric Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORIC stock price target is 43.57 with a high estimate of 52.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 70
Institutional Holdings: 22.64M
% Owned: 63.62%
Shares Outstanding: 35.59M
TypeInstitutionsShares
Increased
20
1.86M
New
20
-588.29K
Decreased
15
131.01K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Founder/Independent Director
Richard Heyman
Chief Executive Officer/Director/Primary Contact
Jacob Chacko
Chief Financial Officer/Primary Contact
Dominic Piscitelli
General Counsel
Christian Kuhlen
Other
Matthew Panuwath
Director
Lori Kunkel
Director
Peter Svennilson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ORIC
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its third product candidate, ORIC-944, being developed for prostate cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ORIC Pharmaceuticals Inc stock information, including NASDAQ:ORIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORIC stock methods without spending real money on the virtual paper trading platform.